IL315228A - Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi - Google Patents

Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi

Info

Publication number
IL315228A
IL315228A IL315228A IL31522824A IL315228A IL 315228 A IL315228 A IL 315228A IL 315228 A IL315228 A IL 315228A IL 31522824 A IL31522824 A IL 31522824A IL 315228 A IL315228 A IL 315228A
Authority
IL
Israel
Prior art keywords
ibrutinib
medicament
bronchiolitis obliterans
obliterans syndrome
treating bronchiolitis
Prior art date
Application number
IL315228A
Other languages
English (en)
Hebrew (he)
Original Assignee
Pharmacyclics Llc
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc, Univ Minnesota filed Critical Pharmacyclics Llc
Publication of IL315228A publication Critical patent/IL315228A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
IL315228A 2013-12-02 2014-12-02 Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi IL315228A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361910944P 2013-12-02 2013-12-02
US201461973178P 2014-03-31 2014-03-31
PCT/US2014/068177 WO2015084857A1 (en) 2013-12-02 2014-12-02 Methods of treating and preventing alloantibody driven chronic graft versus host disease

Publications (1)

Publication Number Publication Date
IL315228A true IL315228A (en) 2024-10-01

Family

ID=53270044

Family Applications (4)

Application Number Title Priority Date Filing Date
IL292522A IL292522A (en) 2013-12-02 2014-12-02 Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi
IL315228A IL315228A (en) 2013-12-02 2014-12-02 Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi
IL245715A IL245715A0 (en) 2013-12-02 2016-05-18 Methods for the treatment and prevention of chronic graft-versus-host disease prevented using alloantibody
IL276683A IL276683A (en) 2013-12-02 2020-08-12 Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL292522A IL292522A (en) 2013-12-02 2014-12-02 Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL245715A IL245715A0 (en) 2013-12-02 2016-05-18 Methods for the treatment and prevention of chronic graft-versus-host disease prevented using alloantibody
IL276683A IL276683A (en) 2013-12-02 2020-08-12 Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi

Country Status (14)

Country Link
US (6) US20150157634A1 (enExample)
EP (1) EP3076975A4 (enExample)
JP (5) JP2017501140A (enExample)
KR (2) KR20160085817A (enExample)
CN (2) CN110478353B (enExample)
AU (4) AU2014360758B2 (enExample)
BR (1) BR112016012158A2 (enExample)
CA (2) CA2932255C (enExample)
EA (1) EA201691020A1 (enExample)
IL (4) IL292522A (enExample)
MX (2) MX389020B (enExample)
PH (2) PH12020552048A1 (enExample)
TW (3) TWI743019B (enExample)
WO (1) WO2015084857A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250151610A (ko) 2012-06-04 2025-10-21 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
CA2928721C (en) * 2013-10-25 2020-12-22 Pharmacyclics Llc Use of ibrutinib for treating and preventing chronic graft versus host disease
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
ES2863700T3 (es) 2016-03-22 2021-10-11 Mayo Found Medical Education & Res Uso de inhibidores de ácido graso sintasa para tratar la fibrosis
WO2018002958A1 (en) * 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
US20200054721A1 (en) * 2016-10-21 2020-02-20 Bruce R. Blazar Materials and methods for treating or preventing graft-versus-host-disease
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
US12496303B2 (en) 2020-10-19 2025-12-16 Washington University Conditioning agents for use in allogeneic hematopoietic stem cell transplantation
US20240025990A1 (en) * 2020-12-01 2024-01-25 City Of Hope Prevention and treatment of graft-versus-host disease (gvhd)
EP4284434A4 (en) * 2021-01-30 2024-12-25 BeiGene Switzerland GmbH METHODS FOR TREATING CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION USING BTK INHIBITORS
US20240287781A1 (en) 2023-02-28 2024-08-29 Toto Ltd. Wall-mounted flush toilet

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US20060182723A1 (en) * 2005-01-25 2006-08-17 Spellberg Brad J Methods for treating refractory infections in neutropenic individuals
US7625880B2 (en) * 2006-01-13 2009-12-01 Pharmacyclics, Inc. Inhibitors of tyrosine kinases and uses thereof
DK2529622T3 (en) * 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE
US20110224235A1 (en) * 2008-07-16 2011-09-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US8765754B2 (en) * 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
AU2010286351A1 (en) * 2009-08-31 2012-03-15 Amplimmune, Inc. B7-H4 fusion proteins and methods of use thereof
US20120071497A1 (en) * 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
KR101580714B1 (ko) * 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
KR20140058543A (ko) * 2011-07-08 2014-05-14 노파르티스 아게 신규 피롤로 피리미딘 유도체
US9522917B2 (en) * 2012-04-11 2016-12-20 Acerta Pharma B.V. Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
JP6257600B2 (ja) * 2012-05-25 2018-01-10 スローン ケタリング インスティテュート フォア キャンサー リサーチ Ｇｉ症候群及び移植片対宿主病の治療方法
WO2014127200A1 (en) * 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
CA2928721C (en) * 2013-10-25 2020-12-22 Pharmacyclics Llc Use of ibrutinib for treating and preventing chronic graft versus host disease
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor

Also Published As

Publication number Publication date
IL292522A (en) 2022-06-01
PH12016501051A1 (en) 2016-08-15
PH12020552048A1 (en) 2022-05-11
AU2014360758B2 (en) 2020-03-26
KR20230104754A9 (ko) 2024-11-15
AU2022203810B2 (en) 2024-10-03
KR20160085817A (ko) 2016-07-18
AU2020204276A1 (en) 2020-07-16
IL245715A0 (en) 2016-07-31
EP3076975A4 (en) 2017-05-03
WO2015084857A1 (en) 2015-06-11
MX389020B (es) 2025-03-20
JP2017501140A (ja) 2017-01-12
JP2025118595A (ja) 2025-08-13
TWI743019B (zh) 2021-10-21
AU2022203810A1 (en) 2022-06-23
CN110478353A (zh) 2019-11-22
JP2023029899A (ja) 2023-03-07
US20250381188A1 (en) 2025-12-18
JP2020105181A (ja) 2020-07-09
JP2024072291A (ja) 2024-05-27
TW202402295A (zh) 2024-01-16
CA2932255C (en) 2023-10-10
IL276683A (en) 2020-09-30
CN110478353B (zh) 2022-12-30
US20180078558A1 (en) 2018-03-22
CN105939717B (zh) 2019-09-13
US20230100137A1 (en) 2023-03-30
AU2024278490A1 (en) 2025-01-09
CN105939717A (zh) 2016-09-14
TW201605454A (zh) 2016-02-16
TW202228700A (zh) 2022-08-01
EP3076975A1 (en) 2016-10-12
MX2022000209A (es) 2022-02-03
CA2932255A1 (en) 2015-06-11
US20210177854A1 (en) 2021-06-17
MX2016006955A (es) 2016-09-07
CA3210338A1 (en) 2015-06-11
BR112016012158A2 (pt) 2017-09-26
AU2014360758A1 (en) 2016-06-16
US20150157634A1 (en) 2015-06-11
US20240293409A1 (en) 2024-09-05
KR20230104754A (ko) 2023-07-10
EA201691020A1 (ru) 2017-01-30

Similar Documents

Publication Publication Date Title
IL276683A (en) Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi
IL269983B (en) Improved auto injector
IL263026A (en) Combination therapy containing ibrutinib
GB2486748B (en) Autoinjector devices
IL241347A0 (en) Methods for obtaining medically effective doses of anti-cd47 agents
IL243225B (en) Self-injecting syringe
IL243224A0 (en) Self-injecting syringe
LT2699293T (lt) Automatinio purškimo prietaisas
IL232690A0 (en) Self-injecting syringe
SG10201708409VA (en) Medicament device
IL232694A0 (en) Self-injecting syringe
LT2701773T (lt) Injekcinio švirkšto dozės kreiptuvai
HUE051933T2 (hu) Egyszer használatos nedvszívó termékek
SG2014010490A (en) Combination treatments for hepatitis c
IL232124A0 (en) Automatic injection device
PL2489413T3 (pl) Przyrząd terapeutyczny
EP2859909A4 (en) SELF-INJECTION MECHANISM FOR USE ON THE SKIN
EP2774642A4 (en) SYRINGE
EP2948129A4 (en) THERAPEUTIC COMPOUNDS
GB201314286D0 (en) Therapeutic Compounds
GB201312499D0 (en) Therapeutic compounds
GB201313835D0 (en) A medicament
GB201320905D0 (en) Therapeutic compounds
GB2490723B (en) Modified syringe
GB201320786D0 (en) Medicament